Fully responsible for medical device related services under Tigermed. Engaged in management in biopharmaceutical R&D and production, pharmaceutical product investment management, medical device registration, pharmaceutical and medical device clinical trial field in Chinese and foreign companies, with a deep understanding of Chinese pharmaceutical product transformation, medical device clinical trial management and registration. Master of Biochemistry from East China Normal University, licensed pharmacist, special expert of China Medical Device Industry Association Clinical Trial Branch. Nearly 20 years of practical experience in the pharmaceutical field.

Dr. Xia Chen holds a Doctor of Medicine in Clinical Medicine from Peking Union Medical College and a Doctor degree in Clinical Pharmacology from Leiden University in the Netherlands. She also holds a Master’s degree in Quantitative Pharmacology from the University of Manchester United Kingdom. Prior to joining Tigermed, she has held critical positions including Associate Professor at Clinical Pharmacology Research Center of Peking Union Medical College, Professor of Clinical Pharmacology at Beijing Tiantan Hospital, and Clinical Reviewer at Center for Drug Evaluation (CDE) of NMPA, with 15 years of clinical R&D experience in hospitals and rich academic research experience.

Over 20-year clinical trial experiences, including 9 years in Shanghai Roche to involve project management and monitor activities; meanwhile to responsible for an international multi-center trial as China Local Project Leader. 3-year working experiences as QA manager working with global QA focusing on trial audit in China.

Over 10-year experiences at Tigermed of quality assurance on clinical trial related activities including QMS, auditing as well as GCP training.

Ms. Chengcheng Yang (Grace), MBA, Zhejiang University. Before joining Tigermed, Ms. Chengcheng Yang worked in PricewaterhouseCoopers, Xizi Otis Company ltd, Xizi Group, Baida Group, Shuanglin Biotechnology Company, Zhejiang United Investment Group Co. ltd. (ZUIG) acting the roles as senior auditor, CFO, Executive Director, Managing Director, etc. She is familiar with China, Hong Kong and International Accounting Standards, specializing in the area of corporate finance, taxation, internal control and operational management with over 20 years’ experience in financial management, investment, financing and capital operation of listed companies. 

With a master's degree in pharmacology from Peking Union Medical College, JinLian Li joined Tigermed in 2009 and has over 16 years of experience in clinical research operations and management. In 2019, she was awarded the President's Special Award and began overseeing strategic client management. In October 2024, she took on the role of General Manager of the Domestic Clinical Operations Department for Innovative Drugs, taking full responsibility for clinical operations related to innovative drugs in China. She was also awarded the "Life First" brand ambassador.

She has led and participated in more than 60 domestic and international clinical trials for innovative drugs, covering oncology, hematology, cardiovascular diseases, respiratory conditions, endocrinology, and rheumatology, spanning all phases from I to IV. She has also undergone on-site inspections by the national authorities for over 10 projects, all successfully approved and launched.

With over 20 years of clinical research experience, Jessie is a seasoned industry veteran who has led more than 300 Phase I-IV clinical studies and supported the registration of over 600 drugs and devices globally and regionally. After earning her Master’s and PhD from Iowa State University, Jessie has held diverse roles across all levels of the industry. Since 2019, she has served as the President of Tigermed US, where she has successfully grown the company from a team of one to a thriving organization of industry-leading professionals under her leadership.

Sijia Hu joined Tigermed in February 2006, and transferred to SMO Business Unit in July 2011, where she took charge of large-scale clinical research SMO project management, CRC team system building and operation management. With nearly 20 years of experience in the field of clinical research, she has grown along with the company as one of the first batch of managers, leading her team to achieve remarkable results. She has also actively devoted herself to promoting the development of the industry. She participated in writing and promoting the "Blue Book of China's CRC Industry," led the team to participate in the on-site execution of clinical studies for potential COVID-19 treatment drugs, and was invited as a guest speaker at universities, industry forums, and conferences to share insights on the development of the SMO industry, CRC career information, and organizational management ideas.

EMBA, joined Tigermed in July 2003 and became a member of the Business Development (BD) team in 2006. As the first BD professional at Tigermed, he has been deeply involved in leading the BD team for nearly two decades. Over the years, he has held management positions such as Director of Business Development, Senior Director of Business Development, and Vice President of Business Development. He possesses extensive experience in sales system construction, customer management, and sales team management. As one of the first batch of managers cultivated by Tigermed, Mr. Dai has led the BD team to achieve remarkable results time and again, playing an active role in promoting the steady development of Tigermed within the industry.

Tianrong Ji, M.D, graduated from Peking Union Medical College, Chinese Academy of Medical Sciences in 1994 and has worked at Peking Union Medical College Hospital, Xi’an Janssen, Roche, Baxter, Fresenius-Kabi etc. She joined Tigermed in July 2014, served as the General Manager of TigerYeah Investment, Vice President and Head of Tigermed Investment Bussiness Unit and has more than twenty years of experience in clinical medicine, fund management and corporate M&A.

Ms. Mo Shuang joined Tigermed in April 2013. She has 13 years of legal and compliance work experience, mainly focusing on legal and compliance management in the pharmaceutical field. She has served as the Compliance Legal Director of Tigermed and the Executive Secretary of the Compliance and ESG Committee. She participated in the legal affairs of Tigermed's H-share listing and several investment and M&A transactions. She has in-depth practice and experience accumulation in contract management, investment and M&A legal affairs, compliance system construction, etc.